We investigated the current role of interferon-alpha (IFN alpha) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first-line treatment; (B) patients with comorbidities with first-line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. After a median (range) follow-up of 60 (7-236) months, 55 patients (78%) are still responding. The 5-year progression-free survival was 95%, 68%, and 96% in groups A, B and C respectively. A proportion of patients were monitored through their B-Raf proto-oncogene, serine/threonine kinase (BRAF)-V600E status. IFN alpha remains a possible option in select patients with HCL, where minimal residual disease negativity is achievable.
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects / Assanto, Giovanni M; Riemma, Costantino; Malaspina, Francesco; Perrone, Salvatore; De Luca, Maria L; Pucciarini, Alessandra; Annechini, Giorgia; D'Elia, Gianna M; Martelli, Maurizio; Foà, Robin; Tiacci, Enrico; Pulsoni, Alessandro. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - 194:1(2021), pp. 78-82. [10.1111/bjh.17440]
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects
Assanto, Giovanni M;Riemma, Costantino;Malaspina, Francesco;Perrone, Salvatore;De Luca, Maria L;Annechini, Giorgia;Martelli, Maurizio;Foà, Robin;Tiacci, Enrico;Pulsoni, Alessandro
2021
Abstract
We investigated the current role of interferon-alpha (IFN alpha) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first-line treatment; (B) patients with comorbidities with first-line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. After a median (range) follow-up of 60 (7-236) months, 55 patients (78%) are still responding. The 5-year progression-free survival was 95%, 68%, and 96% in groups A, B and C respectively. A proportion of patients were monitored through their B-Raf proto-oncogene, serine/threonine kinase (BRAF)-V600E status. IFN alpha remains a possible option in select patients with HCL, where minimal residual disease negativity is achievable.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
